Clinical Trials on Attention Deficit Disorder with Hyperactivity in Singapore
Total 12 results
-
National Healthcare Group, SingaporeUniversity of Pennsylvania; Nanyang Technological University; Alexandra Hospital and other collaboratorsCompletedAttention Deficit Hyperactivity Disorder | Conduct Disorder | Oppositional Defiant DisorderSingapore
-
National Healthcare Group, SingaporeDuke-NUS Graduate Medical School; Institute for Infocomm ResearchCompletedAttention Deficit Hyperactivity DisorderSingapore
-
National Healthcare Group, SingaporeDuke-NUS Graduate Medical School; Agency for Science, Technology and Research; Singapore Clinical Research InstituteCompletedAttention Deficit Hyperactivity DisorderSingapore
-
Institute of Mental Health, SingaporeCompletedAutism Spectrum Disorder | Attention Deficit Hyperactivity DisorderSingapore
-
Duke-NUS Graduate Medical SchoolInstitute of Mental Health, Singapore; Agency for Science, Technology and ResearchCompletedAttention Deficit Hyperactivity Disorder | Autism Spectrum DisordersSingapore
-
Novartis PharmaceuticalsCompletedAttention Deficit/Hyperactivity DisorderUnited States, Germany, Singapore, Colombia, Sweden, Belgium, South Africa, Denmark, Norway
-
KK Women's and Children's HospitalSingapore University of Technology and DesignUnknownCough | URTI | Cough Variant Asthma | Cough; Bronchial, With Grippe or InfluenzaSingapore
-
Woodlands Health CampusTan Tock Seng HospitalRecruitingType 2 Diabetes Treated With InsulinSingapore
-
Singapore Chung Hwa Medical InstitutionMinistry of Health, SingaporeRecruitingHypertension | Healthy | Diabete Mellitus | Pre-diabetes | Dyslipidemia Associated With Type II Diabetes MellitusSingapore
-
Tan Tock Seng HospitalNanyang Technological UniversityCompletedStroke | Spinal Cord Injuries | Acquired Brain Injury | Traumatic Brain Injury With Loss of Consciousness | Joint Replacement SurgerySingapore
-
Samsung Medical CenterCompletedPatients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma | Patients Treated With Rituximab-CHOP or Rituximab-CVPKorea, Republic of, Malaysia, Singapore, China
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland